AcuCort AB announced that the company strengthens its organization and hires Ann Gidner as interim CEO. The current CEO Mats Lindfors will continue to work for AcuCort in a consulting role. The change will take effect on January 1, 2020. The current CEO Mats Lindfors has to the board expressed his wishes to scale down his involvement in AcuCort due to family reasons. The now announced change means that Ann Gidner takes over as interim CEO of AcuCort on January 1, 2020. At the same time, Mats Lindfors takes up a consulting role as support during a transitional period and as responsible for certain projects in AcuCort's business plan. The recruitment of a permanent CEO of AcuCort is in progress. Ann Gidner has solid experience from senior positions in the pharmaceutical industry and life science. Her many years of experience includes roles as Head of the CTS Business Unit at Inceptua GmbH in Berlin, Licensing Director at Albumedix A/S (Novozymes Biopharma) and as CEO of the Monocl AB. Ann has built the business model and created strong sales growth at Cambrex Corporation with placement in Sweden and New Jersey, USA, and at Saltigo GmbH with placement in Germany. She is also a board member of SenzaGen AB since 2014.